Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies in Nonmalignant Hematology: Independent Conference Coverage of ASH 2020
  • CME

Hanny Al-Samkari, MD
Mark A. Schroeder, MD
Sujit Sheth, MD
Released: February 11, 2021
Back Next

Introduction

At the 2020 ASH Annual Meeting, new clinical trial data in nonmalignant hematologic disorders were reported, including novel approaches in immune thrombocytopenia (ITP), hereditary blood disorders (hemophilia, sickle cell disease, and β-thalassemia), and therapies for acute or chronic graft-vs-host disease (GVHD). In this module, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, review and discuss the clinical implications of key studies in these hematologic disorders that were presented at the meeting.

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets that can also be found here, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue